Research ArticleClinical Studies
Long-term Progression-free Survival in A Metastatic Pancreatic Cancer Patient Treated with First-line Nab-paclitaxel and Gemcitabine
STEFAN BOECK, MICHAEL HAAS, STEPHAN KRUGER and VOLKER HEINEMANN
In Vivo November 2014, 28 (6) 1189-1192;
STEFAN BOECK
Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany
MICHAEL HAAS
Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany
STEPHAN KRUGER
Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany
VOLKER HEINEMANN
Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany
In this issue
In Vivo
Vol. 28, Issue 6
November-December 2014
Long-term Progression-free Survival in A Metastatic Pancreatic Cancer Patient Treated with First-line Nab-paclitaxel and Gemcitabine
STEFAN BOECK, MICHAEL HAAS, STEPHAN KRUGER, VOLKER HEINEMANN
In Vivo Nov 2014, 28 (6) 1189-1192;
Jump to section
Related Articles
- No related articles found.